Dimethyl fumarate for relapsing remitting multiple sclerosis in people aged 13 years and older

Dimethyl fumarate is in clinical development for patients aged 10 -17 years and older with relapsing-remitting multiple sclerosis (RRMS). Multiple Sclerosis (MS) is a chronic condition that affects the brain and spinal cord, it can lead to increased mortality and is one of the most common causes of disability in younger adults. Relapsing and remitting MS is the most common form of MS with 80% of patients diagnosed with this type and is characterised by repeated episodes of new or worsening symptoms which then improve over time but often do not disappear. Symptoms of MS include fatigue, difficulty walking, vision problems, problems controlling bladder, numbness or stiffness, balance and coordination problems, and cognitive impairment, all impairing the quality of life of a person with MS. However, there are no approved pharmacological treatments for paediatric population with RRMS.